CTI plans for room to grow as cell and gene therapies take off

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/lovelyday12)
(Image: Getty/lovelyday12)

Related tags: CTI Clinical Trial and Consulting Services, cell and gene therapy, Contract research

CTI expects to create up to 50 new jobs over the next several years in response to significant growth in the pharma and biotech industry, specifically in cell and gene therapies, says CEO.

CTI Clinical Trial and Consulting Services (CTI​) is expanding its office footprint in Raleigh, NC, doubling the current space to accommodate immediate and future growth.

The contract research organization (CRO) this week announced plans to expand in the US, as part of which it has moved its West Coast office in San Francisco to a larger space.

“CTI is expanding our team across the US, so we are strategically choosing cities where we can find talented professionals who have experience in our industry,”​ Tim Schroeder, CEO of CTI, told us.

“Raleigh and San Francisco are hubs of talent for the technology, pharma, and research industries, so expanding our presence in these cities is key to recruiting some of that talent,”​ he said.

The company anticipates the expansion will create up to 50 jobs between the two cities over the next several years.

“We are committed to growing in both cities, so we may expand even faster; it just depends on how quickly things progress,”​ said Schroeder.

CTI President Lynn Fallon noted that there has been significant growth in the pharma and biotech industry over the past several years, particularly in the areas of cell and gene therapies, “so we are getting more and more requests to help sponsors with these kinds of programs,”​ she said.

“As demand for our expertise grows, so does our need for more experienced, talented individuals to join our team,”​ Fallon added.

CTI has more than 30 offices worldwide and is currently hiring as it continues to expand its team in the Cincinnati area.

Related topics: Clinical Development, Phase I-IV

Related news

Show more

Related products

show more

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars